Table 4 Onset time of events (days).
SOC | PTs | CDOX | Doxil | Myocet | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | Median (IQR) | Mean | n | Median (IQR) | Mean | n | Median (IQR) | Mean | ||
Blood and lymphatic system disorders | Neutropenia | 75 | 35 (14; 273) | 90.85 | 59 | 17 (10; 47) | 66.35 | 25 | 30 (11.5; 78.5) | 79.68 |
Pancytopenia | 44 | 58.5(15; 123) | 57.89 | 61 | 50 (15; 133.5) | 55.06 | 6 | 80.5 (6.5; 121.5) | 51.75 | |
Thrombocytopenia | 32 | 14 (8; 91) | 39.67 | 52 | 45 (14.25; 102) | 53.74 | 11 | 16 (14; 59) | 45.09 | |
Febrile neutropenia | 124 | 33 (11; 77.25) | 123.37 | 92 | 34 (12; 80.5) | 128.23 | 29 | 12 (9; 86.5) | 104.83 | |
Cardiac disorders | Cardiomyopathy | 24 | 126 (89; 325.5) | 19.79 | 16 | 230 (121.5; 252) | 21.56 | 1 | – | – |
General disorders and administration site conditions | Mucosal inflammation | 24 | 15 (8; 29) | 22.77 | 16 | 11 (6.25; 66) | 23.41 | 7 | 20 (14; 50) | 29.57 |
Infections and infestations | Sepsis | 19 | 24 (9; 101) | 24.82 | 26 | 51.5 (17.75; 107.5) | 31.4 | 11 | 61 (10; 61) | 28 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Malignant neoplasm progression | 11 | 427 (153; 1371) | 52.41 | 63 | 142 (56; 445) | 34.9 | 1 | – | – |
Respiratory, thoracic and mediastinal disorders | Interstitial lung disease | 24 | 105 (51.5; 114) | 37.94 | 58 | 99 (42; 120.25) | 46.33 | 3 | 49 (9; .) | 19.17 |
Pneumonia | 43 | 159 (16; 365) | 52.15 | 37 | 17 (4; 290) | 35.91 | 9 | 90 (41;116) | 48.22 | |
Pleural effusion | 12 | 62 (20.75; 250) | 22.75 | 28 | 79 (19.25; 177.5) | 19.54 | 1 | – | – | |
Skin and subcutaneous tissue disorders | Palmar-plantar erythrodysaesthesia syndrome | 11 | 60 (30; 72) | 46.86 | 74 | 46 (30; 67.75) | 45.28 | 10 | 72 (56.5;96.75) | 69.4 |
Vascular disorders | Pulmonary embolism | 16 | 96.5 (86; 1611) | 29.84 | 25 | 49 (15.5; 95) | 19.46 | 6 | 85 (49.5;200.25) | 27.33 |
